Cardiovascular protective effects and clinical applications of resveratrol

Journal of Medicinal Food

Volumn 20, Issue 4, 2017, Pages 323-334

  Cho, Sanghyun ^a   Namkoong, Kyung ^a   Shin, Minji ^a   Park, Jueun ^a   Yang, Eunyeong ^a   Ihm, Jinsoo ^a   Thu, Vu Thi ^a,b   Kim, Hyoung Kyu ^a,c   Han, Jin ^a  

^a Inje University College of Medicine   (South Korea)

^b VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

^c Inje University   (South Korea)

Author keywords

cardiovascular disease; clinical application; resveratrol

Indexed keywords

ANTIMETABOLITE; RESVERATROL; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; CARDIOTONIC AGENT; PHENOL DERIVATIVE; PLANT EXTRACT; STILBENE DERIVATIVE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTERY WALL; ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; HEART PROTECTION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; PHENOLS; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STILBENES;

EID: 85018586100     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2016.3856     Document Type: Review

References (130)

1. Moodie DS: The global burden of cardiovascular disease. Congenit Heart Dis 2016;11:213
2. Renaud S, de Lorgeril M: Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339: 1523-1526
3. Catalgol B, Batirel S, Taga Y, Ozer NK: Resveratrol: French paradox revisited. Front Pharmacol 2012;3:141
4. Vidavalur R, Otani H, Singal PK, Maulik N: Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol 2006;11:217-225
5. Couzin J: Women's health. Study yields murky signals on lowfat diets and disease. Science 2006;311:755
6. Liu BL, Zhang X, Zhang W, Zhen HN: New enlightenment of French paradox: Resveratrol's potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther 2007;6: 1833-1836
7. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126
8. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-261
9. Aviram M, Rosenblat M: Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-1316
10. Wadsworth TL, Koop DR: Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem Pharmacol 1999;57:941-949
11. Voloshyna I, Hai O, Littlefield MJ, Carsons S, Reiss AB: Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARc and adenosine. Eur J Pharmacol 2013;698:299-309
12. Voloshyna I, Hussaini SM, Reiss AB: Resveratrol in cholesterol metabolism and atherosclerosis. J Med Food 2012;15:763-773
13. Majdalawieh A, Ro HS: PPARc1 and LXRa face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl Recept Signal 2010;8:e004
14. O'Leary KA, de Pascual-Teresa S, Needs PW, Bao YP, O'Brien NM, Williamson G: Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res 2004;551: 245-254
15. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARc. Cell 1998;93:229-240
16. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ: An oxysterol signalling pathway mediated by the nuclear receptor LXR a. Nature 1996;383:728-731
17. Lehrke M, Lazar MA: The many faces of PPARc. Cell 2005;123:993-999
18. Cheng G, Zhang X, Gao D, Jiang X, Dong W: Resveratrol inhibits MMP-9 expression by up-regulating PPAR a expression in an oxygen glucose deprivation-exposed neuron model. Neurosci Lett 2009;451:105-108
19. Joseph SB, McKilligin E, Pei L, et al.: Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002;99:7604-7609
20. Sevov M, Elfineh L, Cavelier LB: Resveratrol regulates the expression of LXR-a in human macrophages. Biochem Biophys Res Commun 2006;348:1047-1054
21. Voloshyna I, Reiss AB: The ABC transporters in lipid flux and atherosclerosis. Prog Lipid Res 2011;50:213-224
22. Kinlay S, Behrendt D, Wainstein M, et al.: Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001;104:1114-1118
23. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109:III27-III32
24. Rubbo H, Botti H, Batthyany C, Trostchansky A, Denicola A, Radi R: Antioxidant and diffusion properties of nitric oxide in low-density lipoprotein. Methods Enzymol 2002;359:200-209
25. Lin MT, Yen ML, Lin CY, Kuo ML: Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 2003;64:1029-1036
26. Zou JG, Wang ZR, Huang YZ, Cao KJ, Wu JM: Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med 2003;11:317-320
27. Csiszar A, Wang M, Lakatta EG, Ungvari Z: Inflammation and endothelial dysfunction during aging: Role of NF-kappaB. J Appl Physiol (1985) 2008;105:1333-1341
28. Csiszar A, Ungvari Z, Edwards JG, et al.: Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 2002;90:1159-1166
29. van der Loo B, Labugger R, Skepper JN, et al.: Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 2000;192:1731-1744
30. Adler A, Messina E, Sherman B, et al.: NAD(P)H oxidasegenerated superoxide anion accounts for reduced control of myocardial O2 consumption by NO in old Fischer 344 rats. Am J Physiol Heart Circ Physiol 2003;285:H1015-H1022
31. Donato AJ, Eskurza I, Silver AE, et al.: Direct evidence of endothelial oxidative stress with aging in humans: Relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB. Circ Res 2007;100:1659-1666
32. Hoffmann J, Haendeler J, Aicher A, et al.: Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: Important role of nitric oxide. Circ Res 2001;89:709-715
33. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G: Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiol Genomics 2004;17:21-30
34. Ungvari Z, Labinskyy N, Gupte S, Chander PN, Edwards JG, Csiszar A: Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats. Am J Physiol Heart Circ Physiol 2008;294:H2121-H2128
35. Addabbo F, Ratliff B, Park HC, et al.: The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: Proteomic approach. Am J Pathol 2009;174:34-43
36. Csiszar A, Labinskyy N, Pinto JT, et al.: Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 2009;297:H13-H20
37. Li W, Mital S, Ojaimi C, Csiszar A, Kaley G, Hintze TH: Premature death and age-related cardiac dysfunction in male eNOS-knockout mice. J Mol Cell Cardiol 2004;37:671-680
38. Juric D, Wojciechowski P, Das DK, Netticadan T: Prevention of concentric hypertrophy and diastolic impairment in aorticbanded rats treated with resveratrol. Am J Physiol Heart Circ Physiol 2007;292:H2138-H2143
39. Gurusamy N, Ray D, Lekli I, Das DK: Red wine antioxidant resveratrol-modified cardiac stem cells regenerate infarcted myocardium. J Cell Mol Med 2010;14:2235-2239
40. Csiszar A, Labinskyy N, Olson S, et al.: Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009;54:668-675
41. Zhang H, Zhang J, Ungvari Z, Zhang C: Resveratrol improves endothelial function: Role of TNFa and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009;29:1164-1171
42. Ungvari Z, Labinskyy N, Mukhopadhyay P, et al.: Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2009;297: H1876-H1881
43. Zhang H, Morgan B, Potter BJ, et al.: Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 2010;299: H985-H994
44. Bradamante S, Barenghi L, Piccinini F, et al.: Resveratrol provides late-phase cardioprotection by means of a nitric oxide-and adenosine-mediated mechanism. Eur J Pharmacol 2003;465: 115-123
45. Pearson KJ, Baur JA, Lewis KN, et al.: Resveratrol delays agerelated deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008; 8:157-168
46. Ungvari Z, Orosz Z, Labinskyy N, et al.: Increased mitochondrial H2O2 production promotes endothelial NFjB activation in aged rat arteries. Am J Physiol Heart Circ Physiol 2007;293: H37-H47
47. Chow SE, Hshu YC, Wang JS, Chen JK: Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol (1985) 2007;102:1520-1527
48. Hector KL, Lagisz M, Nakagawa S: The effect of resveratrol on longevity across species: A meta-analysis. Biol Lett 2012;8: 790-793
49. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217-223
50. Organization WH: Global health risks: mortality and burden of disease attributable to selected major risks. World Health Organization, Geneva, 2009
51. Menzies KJ, Singh K, Saleem A, Hood DA: Sirtuin 1-mediated effects of exercise and resveratrol on mitochondrial biogenesis. J Biol Chem 2013;288:6968-6979
52. Stocker R, Perrella MA: Heme oxygenase-1: A novel drug target for atherosclerotic diseases? Circulation 2006;114:2178-2189
53. Chao HH, Juan SH, Liu JC, et al.: Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. Eur J Pharmacol 2005;515:1-9
54. Liu JC, Chen JJ, Chan P, Cheng CF, Cheng TH: Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 2003;42:1198-1205
55. Miyazaki R, Ichiki T, Hashimoto T, et al.: SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008;28:1263-1269
56. Hamza SM, Dyck JR: Systemic and renal oxidative stress in the pathogenesis of hypertension: Modulation of long-term control of arterial blood pressure by resveratrol. Front Physiol 2014; 5:292
57. Liu FC, Tsai HI, Yu HP: Organ-Protective effects of red wine extract, resveratrol, in oxidative stress-mediated reperfusion injury. Oxid Med Cell Longev 2015;2015:568634
58. Forstermann U, Li H: Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 2011;164:213-223
59. Raj P, Aloud BM, Louis XL, Yu L, Zieroth S, Netticadan T: Resveratrol is equipotent to perindopril in attenuating postinfarct cardiac remodeling and contractile dysfunction in rats. J Nutr Biochem 2016;28:155-163
60. Fukuda S, Kaga S, Zhan L, et al.: Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys 2006;44:43-49
61. Thirunavukkarasu M, Penumathsa SV, Koneru S, et al.: Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007;43:720-729
62. Gambini J, Ingles M, Olaso G, et al.: Properties of resveratrol: In vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev 2015;2015:837042
63. Movahed A, Yu L, Thandapilly SJ, Louis XL, Netticadan T: Resveratrol protects adult cardiomyocytes against oxidative stress mediated cell injury. Arch Biochem Biophys 2012;527: 74-80
64. Wu H, Li GN, Xie J, et al.: Resveratrol ameliorates myocardial fibrosis by inhibiting ROS/ERK/TGF-b/periostin pathway in STZ-induced diabetic mice. BMC Cardiovasc Disord 2016;16:5
65. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck JR: Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009;119: 1643-1652
66. Dolinsky VW, Chakrabarti S, Pereira TJ, et al.: Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 2013;1832:1723-1733
67. Hao E, Lang F, Chen Y, et al.: Resveratrol alleviates endotoxininduced myocardial toxicity via the Nrf2 transcription factor. PLoS One 2013;8:e69452
68. Fukui M, Choi HJ, Zhu BT: Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radic Biol Med 2010;49:800-813
69. Selvetella G, Hirsch E, Notte A, Tarone G, Lembo G: Adaptive and maladaptive hypertrophic pathways: Points of convergence and divergence. Cardiovasc Res 2004;63:373-380
70. Behbahani J, Thandapilly SJ, Louis XL, et al.: Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens 2010;23:1273-1278
71. Thandapilly SJ, Wojciechowski P, Behbahani J, et al.: Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010;23:192-196
72. Gupta PK, DiPette DJ, Supowit SC: Protective effect of resveratrol against pressure overload-induced heart failure. Food Sci Nutr 2014;2:218-229
73. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR: Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004;279:32771-32779
74. Noga AA, Soltys CL, Barr AJ, Kovacic S, Lopaschuk GD, Dyck JR: Expression of an active LKB1 complex in cardiac myocytes results in decreased protein synthesis associated with phenylephrine-induced hypertrophy. Am J Physiol Heart Circ Physiol 2007;292:H1460-H1469
75. Chan AY, Dolinsky VW, Soltys CL, et al.: Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 2008;283:24194-24201
76. Dorri Mashhadi F, Zavvar Reza J, Jamhiri M, Hafizi Z, Zare Mehrjardi F, Safari F: The effect of resveratrol on angiotensin II levels and the rate of transcription of its receptors in the rat cardiac hypertrophy model. J Physiol Sci 2016;67:303-309
77. Yin K, Zhao L, Feng D, et al.: Resveratrol attenuated low ambient temperature-induced myocardial hypertrophy via inhibiting cardiomyocyte apoptosis. Cell Physiol Biochem 2015; 35:2451-2462
78. Wang B, Yang Q, Sun YY, et al.: Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J Cell Mol Med 2014;18:1599-1611
79. Tang G, Peng L, Qian G, et al.: Resveratrol increases microRNA-130a expression to promote angiogenesis and improve heart functions in mice after myocardial infarction. Exp Mol Pathol 2016 [Epub ahead of print]; DOI: 10.1016/j .yexmp.2016.10.005
80. Yang B, Ma S, Wang YB, et al.: Resveratrol exerts protective effects on anoxia/reoxygenation injury in cardiomyocytes via miR-34a/Sirt1 signaling pathway. Eur Rev Med Pharmacol Sci 2016;20:2734-2741
81. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229
82. Osman AM, Bayoumi HM, Al-Harthi SE, Damanhouri ZA, Elshal MF: Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int 2012;12:47
83. Fan Y, Chen M, Meng J, et al.: Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity. PLoS One 2014;9:e105890
84. Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R: Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord 2014;12:497-501
85. Kaur J: A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;2014:943162
86. Parikh RM, Mohan V: Changing definitions of metabolic syndrome. Indian J Endocrinol Metab 2012;16:7-12
87. Grundy SM: Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012;59:635-643
88. Bagul PK, Middela H, Matapally S, et al.: Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 2012; 66:260-268
89. Robich MP, Osipov RM, Chu LM, et al.: Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur J Pharmacol 2011; 664:45-53
90. Burgess TA, Robich MP, Chu LM, Bianchi C, Sellke FW: Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch Surg 2011; 146:556-564
91. Elmadhun NY, Lassaletta AD, Chu LM, Bianchi C, Sellke FW: Vodka and wine consumption in a swine model of metabolic syndrome alters insulin signaling pathways in the liver and skeletal muscle. Surgery 2012;152:414-422
92. Fulda S: Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today 2010;15:757-765
93. He S, Yan X: From resveratrol to its derivatives: New sources of natural antioxidant. Curr Med Chem 2013;20:1005-1017
94. Ruan BF, Lu XQ, Song J, Zhu HL: Derivatives of resveratrol: Potential agents in prevention and treatment of cardiovascular disease. Curr Med Chem 2012;19:4175-4183
95. Jeong SH, Hanh TM, Kim HK, et al.: HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/ reoxygenation injury via attenuating mitochondrial damage. Bioorg Med Chem Lett 2013;23:4225-4229
96. Magyar K, Halmosi R, Palfi A, et al.: Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012;50:179-187
97. Agarwal B, Campen MJ, Channell MM, et al.: Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol 2013;166:246-248
98. Tome-Carneiro J, Gonzalvez M, Larrosa M, et al.: Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res 2012;56:810-821
99. Carrizzo A, Puca A, Damato A, et al.: Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 2013;62: 359-366
100. Tome-Carneiro J, Gonzalvez M, Larrosa M, et al.: Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: A triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2013;27:37-48
101. Bentzon JF, Otsuka F, Virmani R, Falk E: Mechanisms of plaque formation and rupture. Circ Res 2014;114:1852-1866
102. Bhatt JK, Thomas S, Nanjan MJ: Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012;32:537-541
103. Timmers S, Konings E, Bilet L, et al.: Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14:612-622
104. Bo S, Ciccone G, Castiglione A, et al.: Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem 2013;20:1323-1331
105. Zordoky BNM, Robertson IM, Dyck JRB: Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochem Biophys Acta 2015;1852: 1155-1177
106. Sahebkar A: Effects of resveratrol supplementation on plasma lipids: A systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2013;71:822-835
107. Smulyan H, Mookherjee S, Safar ME: The two faces of hypertension: Role of aortic stiffness. J Am Soc Hypertens 2016; 10:175-183
108. Liu Y, Ma W, Zhang P, He S, Huang D: Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials. Clin Nutr 2015;34:27-34
109. Yoshino J, Conte C, Fontana L, et al.: Resveratrol supplementation does not improve metabolic function in non-obese women with normal glucose tolerance. Cell Metab 2012;16: 658-664
110. Tome-Carneiro J, Gonzalvez M, Larrosa M, et al.: One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 2012;110:356-363
111. Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI: Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013;29:178-183
112. Shanaki Bavarsad M, Golmohammadi T, Hossein-nezhad A, et al.: Effects of resveratrol on crosstalk between canonical bcatenin/ Wnt and FOXO pathways in coronary artery disease patients with metabolic syndrome: A case control study. Iran J Pharm Res 2016;15:547-559
113. Anton SD, Embry C, Marsiske M, et al.: Safety and metabolic outcomes of resveratrol supplementation in older adults: Results of a twelve-week, placebo-controlled pilot study. Exp Gerontol 2014;0:181-187
114. Huynh K, Bernardo BC, McMullen JR, Ritchie RH: Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014; 142:375-415
115. Varga ZV, Giricz Z, Liaudet L, Hasko G, Ferdinandy P, Pacher P: Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta 2015;1852:232-242
116. Soare A, Weiss EP, Holloszy JO, Fontana L: Multiple dietary supplements do not affect metabolic and cardiovascular health. Aging 2013;4:4
117. Kennedy DO, Wightman EL, Reay JL, et al.: Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 2010;91:1590-1597
118. Smoliga JM, Vang O, Baur JA: Challenges of translating basic research into therapeutics: Resveratrol as an example. J Gerontol A Biol Sci Med Sci 2012;67A:158-167
119. Poulsen MM, Vestergaard PF, Clasen BF, et al.: High-dose resveratrol supplementation in obese men: An investigatorinitiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62:1186-1195
120. Smoliga JM, Colombo ES, Campen MJ: A healthier approach to clinical trials evaluating resveratrol for primary prevention of agerelated diseases in healthy populations. Aging 2013;5:495-506
121. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S: Resveratrol: Review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv 2014;11:1285-1298
122. Francioso A, Mastromarino P, Restignoli R, Boffi A, d'Erme M, Mosca L: Improved stability of trans-resveratrol in aqueous solutions by carboxymethylated (1,3/1,6)-b-D-glucan. J Agric Food Chem 2014;62:1520-1525
123. Johnson JJ, Nihal M, Siddiqui IA, et al.: Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res 2011;55:1169-1176
124. Howitz KT, Bitterman KJ, Cohen HY, et al.: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-196
125. Movahed A, Nabipour I, Lieben Louis X, et al.: Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med 2013;2013:11
126. Crandall JP, Oram V, Trandafirescu G, et al.: Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012;67:1307-1312
127. Fujitaka K, Otani H, Jo F, et al.: Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res 2011;31:842-847
128. Wong RHX, Howe PRC, Buckley JD, Coates AM, Kunz I, Berry NM: Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2011;21:851-856
129. Wightman EL, Reay JL, Haskell CF, Williamson G, Dew TP, Kennedy DO: Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebocontrolled, cross-over investigation. Br J Nutr 2014;112:203-213
130. Wong RH, Berry NM, Coates AM, et al.: Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens 2013;31:1819-1827